Search results for: Cervical Cancer
Filter search results
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…The gaps in funding and implementation are a significant barrier for patients with lung cancer benefitting from the use of NGS testing and the advanced precision treatments it facilitates. In…
Government and Charity Funding of Cancer Research: Public Preferences and Choices
13 October 2015
…of cancer appears to be a more important driver of people’s decisions to donate to cancer research charities. If the government were to cut funding for cancer research, it seems…
Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London
15 May 2018
…adviser offering insights on clinical cancer outcomes and cancer care. This research will support a better understanding of what is of ‘value’ in the treatment of cancer patients that…
OHE Lunchtime Seminar: How Cost-Effective are New Cancer Drugs in the U.S.?
18 September 2017, 11:00pm
OHE Lunchtime Seminar with Professor Frank Lichtenberg, Columbia University. The number of drugs approved by the FDA for treating cancer has increased substantially during the last 40 years. Moreover, cancer…
Prevention in the NHS 10 Year Health Plan: Promise, limits, and the path forward
17 September 2025
…population through immunisation, including: Increasing uptake of HPV vaccines to support the aim of eliminating cervical cancer by 2040 Delivering 10,000 cancer vaccines to patients in clinical trials in the…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…for some cancer medicines into the NHS in England, and identified the treatment outcomes that people affected by cancer consider most important. The first phase of the study ‘Making Outcome-Based…
NGS testing for lung cancer across Europe still limited, despite clear case for adoption
10 July 2023
…for expanding its use in lung cancer. Coupled with potential efficiency savings, and a chance to improve patient outcomes, the case for investing in NGS strengthens.” Lung cancer affects hundreds…
What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment
2 January 2020
…of cancer on the NHS: around 90-95 percent of patients suspected of having cancer are not diagnosed with cancer. However, all potential cancer patients proceed along the same cancer pathway…
OHE Lunchtime Seminar: How Cost-Effective are New Cancer Drugs in the U.S.?
2 August 2017
…measured as the ratio of the impact of new cancer drugs on medical expenditure to their impact on the number of years of potential life lost due to cancer. The…